Experienced in Brain Tumor

Dr. Vandana G. Abramson

Oncology | Hematology
Vanderbilt Health Clinicians, LLC
1003 Reserve Blvd, 
Spring Hill, TN 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Experienced in Brain Tumor
Vanderbilt Health Clinicians, LLC
1003 Reserve Blvd, 
Spring Hill, TN 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Vandana Abramson is an Oncologist and a Hematologist in Spring Hill, Tennessee. Dr. Abramson is rated as an Experienced provider by MediFind in the treatment of Brain Tumor. Her top areas of expertise are Breast Cancer, Triple-Negative Breast Cancer, HER-2 Positive Breast Cancer, Angiosarcoma, and Tissue Biopsy. Dr. Abramson is currently accepting new patients.

Her clinical research consists of co-authoring 104 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 5 articles and participated in 1 clinical trial in the study of Brain Tumor.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in PA
Hospital Affiliations
Vanderbilt University Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alliant Health
  • HMO
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Farm Bureau Health Plans
  • HMO
  • MEDICARE MAPD
  • MEDICARE PDP
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
MetLife
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

VANDERBILT HEALTH CLINICIANS, LLC
1003 Reserve Blvd, Spring Hill, TN 37174
Other Locations
VANDERBILT HEALTH CLINICIANS, LLC
719 Thompson Ln, Nashville, TN 37204

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared with T-DM1 and Tucatinib
Enrollment Status: Recruiting
Publish Date: January 13, 2025
Intervention Type: Other, Biological, Drug
Study Drugs: Trastuzumab Emtansine, Tucatinib
Study Phase: Phase 3
A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients With Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker
A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients With Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker
Enrollment Status: Completed
Publish Date: September 26, 2025
Intervention Type: Drug
Study Drugs: Paclitaxel, Cisplatin
Study Phase: Phase 2
A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination With Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
A Phase II Open-Label, Randomized Study of PARP Inhibition (Olaparib) Either Alone or in Combination With Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-Positive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 24, 2025
Intervention Type: Procedure, Drug, Other
Study Drugs: Atezolizumab, Olaparib
Study Phase: Phase 2
A Phase II Study of Niraparib With Dostarlimab Therapy as Neoadjuvant Treatment for Patients With BRCA-mutated Breast Cancer
A Phase II Study of Niraparib With Dostarlimab Therapy as Neoadjuvant Treatment for Patients With BRCA-mutated Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 28, 2025
Intervention Type: Drug
Study Drugs: Niraparib, Dostarlimab
Study Phase: Phase 2
A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) With Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients With Primary Operable HER2-Positive Breast Cancer
A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) With Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients With Primary Operable HER2-Positive Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 01, 2025
Intervention Type: Drug, Procedure
Study Drugs: Trastuzumab, Pertuzumab
Study Phase: Phase 2
A Randomized Phase II Study of Pembrolizumab, an Anti-Programmed Cell Death (PD)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
A Randomized Phase II Study of Pembrolizumab, an Anti-Programmed Cell Death (PD)-1 Antibody, in Combination With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
Enrollment Status: Completed
Publish Date: May 02, 2025
Intervention Type: Drug, Biological
Study Drugs: Pembrolizumab, Carboplatin, Trastuzumab
Study Phase: Phase 2
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response
Enrollment Status: Active_not_recruiting
Publish Date: April 18, 2025
Intervention Type: Procedure, Biological, Drug, Radiation
Study Drugs: Docetaxel, Nab-Paclitaxel, Paclitaxel, Pertuzumab, Trastuzumab, Trastuzumab Emtansine
Study Phase: Phase 2
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Enrollment Status: Active_not_recruiting
Publish Date: March 17, 2025
Intervention Type: Drug
Study Drugs: Trastuzumab, Paclitaxel, Trastuzumab emtansine
Study Phase: Phase 2
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: December 27, 2024
Intervention Type: Drug, Other
Study Drugs: Anastrozole, Everolimus, Exemestane, Goserelin Acetate, Letrozole, Leuprolide Acetate, Tamoxifen Citrate
Study Phase: Phase 3
A Phase II Trial of Atezolizumab (Anti-PDL1) With Carboplatin in Patients With Metastatic Triple Negative Breast Cancer
A Phase II Trial of Atezolizumab (Anti-PDL1) With Carboplatin in Patients With Metastatic Triple Negative Breast Cancer
Enrollment Status: Completed
Publish Date: December 12, 2024
Intervention Type: Other, Drug
Study Drugs: atezolizumab, carboplatin
Study Phase: Phase 2
A Phase Ib Trial of Fulvestrant, Palbociclib (CDK4/6 Inhibitor) and Erdafitinib (JNJ- 42756493,Pan-FGFR Tyrosine Kinase Inhibitor) in ER+/HER2-/FGFR-Amplified Metastatic Breast Cancer (MBC)
A Phase Ib Trial of Fulvestrant, Palbociclib (CDK4/6 Inhibitor) and Erdafitinib (JNJ- 42756493,Pan-FGFR Tyrosine Kinase Inhibitor) in ER+/HER2-/FGFR-Amplified Metastatic Breast Cancer (MBC)
Enrollment Status: Completed
Publish Date: November 14, 2024
Intervention Type: Drug
Study Drugs: Erdafitinib, Palbociclib, Fulvestrant
Study Phase: Phase 1
A Phase Ib Trial of LY2157299 (TGFβR1 Kinase Inhibitor) With Paclitaxel in Patients With Triple Negative Metastatic Breast Cancer
A Phase Ib Trial of LY2157299 (TGFβR1 Kinase Inhibitor) With Paclitaxel in Patients With Triple Negative Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: November 22, 2023
Intervention Type: Other, Drug
Study Drugs: Galunisertib, Paclitaxel
Study Phase: Phase 1
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drugs: tucatinib, capecitabine, trastuzumab
Study Phase: Phase 2
A Phase Ib/II Trial of Taselisib (GDC-0032), a PI3K Inhibitor, in Combination With Enzalutamide in Patients With Androgen Receptor Positive Triple Negative Metastatic Breast Cancer
A Phase Ib/II Trial of Taselisib (GDC-0032), a PI3K Inhibitor, in Combination With Enzalutamide in Patients With Androgen Receptor Positive Triple Negative Metastatic Breast Cancer
Enrollment Status: Terminated
Publish Date: August 22, 2022
Intervention Type: Drug, Other
Study Drugs: Enzalutamide, Taselisib
Study Phase: Phase 1/Phase 2
View 13 Less Clinical Trials

103 Total Publications

Multiplex Spatial Proteomic Analysis of HER2-Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response.
Multiplex Spatial Proteomic Analysis of HER2-Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response.
Journal: JCO precision oncology
Published: April 03, 2025
Similar Doctors
Distinguished in Brain Tumor
Dr. Kent C. Shih
Hematology Oncology | Hematology | Oncology
Distinguished in Brain Tumor
Dr. Kent C. Shih
Hematology Oncology | Hematology | Oncology

Tennessee Oncology PLLC

4220 Harding Pike, 
Nashville, TN 
 (27.3 miles away)
615-385-3751
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Kent Shih is a Hematologist Oncology specialist and a Hematologist in Nashville, Tennessee. Dr. Shih is rated as a Distinguished provider by MediFind in the treatment of Brain Tumor. His top areas of expertise are Glioblastoma, Glioma, Metastatic Brain Tumor, Bone Graft, and Vertebroplasty. Dr. Shih is currently accepting new patients.

Experienced in Brain Tumor
Dr. Dana Thompson
Hematology | Oncology
Experienced in Brain Tumor
Dr. Dana Thompson
Hematology | Oncology

Tennessee Oncology PLLC

1750 Cedar Ln, Suite 200, 
Tullahoma, TN 
 (44.7 miles away)
615-333-2481
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dana Thompson is a Hematologist and an Oncologist in Tullahoma, Tennessee. Dr. Thompson is rated as a Distinguished provider by MediFind in the treatment of Brain Tumor. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Severe Congenital Neutropenia, Colorectal Cancer, and Bone Marrow Aspiration.

Advanced in Brain Tumor
Dr. Todd M. Bauer
Hematology Oncology | Hematology | Oncology
Advanced in Brain Tumor
Dr. Todd M. Bauer
Hematology Oncology | Hematology | Oncology

Tennessee Oncology PLLC

250 25th Ave N, Suite 200, 
Nashville, TN 
 (29.1 miles away)
615-320-5090
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Todd Bauer is a Hematologist Oncology specialist and a Hematologist in Nashville, Tennessee. Dr. Bauer is rated as a Distinguished provider by MediFind in the treatment of Brain Tumor. His top areas of expertise are Lung Cancer, Familial Colorectal Cancer, Iron Deficiency Anemia, and Familial Pancreatic Cancer. Dr. Bauer is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Abramson's expertise for a condition
ConditionClose
View All 15 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile